BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2017

Mar 10, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2017-03-08

Reporting Person: STAAB THOMAS R II (Senior Vice President and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-03-08	Common Stock	M	6500	$3.78	Acquired	123813	Direct
2017-03-08	Common Stock	S	3250	$8.20	Disposed	120563	Direct
2017-03-08	Common Stock	S	3250	$8.65	Disposed	117313	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-03-08	Emp. Stock Option (Right to Buy)	$3.78	M	6500	Disposed	2021-07-01	Common Stock (6500)	Direct

Footnotes

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016.